MSH2 and sarcoma: MSH2 alterations were present in 32 patients overall, most commonly in the STS cohort (n=22), including nine patients with sarcoma NOS, three patients with undifferentiated pleomorphic sarcoma, two patients with leiomyosarcoma, two patients with rhabdomyosarcoma, one patient with pleomorphic liposarcoma, one patient with well-differentiated liposarcoma, one patient with liposarcoma NOS, one patient with solitary fibrous tumor, one patient with angiosarcoma, and one patient with alveolar soft part sarcoma.